Abstract: Malignant peritoneal mesothelioma(MPM) is a rare and aggressive tumor and highly associated with asbestos exposure. Due to the wide application of asbestos materials in the early stage, the incidence of MPM is increasing now. The symptoms of MPM are atypical, so most of patients are in the late stage when diagnosed. And the prognosis is so poor that the median survival time is only 12 months. Now the main treatment of MPM is CRS-HIPEC, at the same time, a number of immune and targeted treatments are under study. This article reviews the current status of treatment on MPM, aiming to improve the understandings of this disease and provide a reference for the clinical diagnosis and treatment.